Evidence map›Paper›PMID 40475412›Full record

ArticlebioRxiv : the preprint server for biology2025

Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma.

Ye Zhang, Lydie Debaize, Adam Langenbucher, Jenalyn Weekes, Ioulia Vogiatzi, Teemu P Miettinen, Mingzeng Zhang, Emily Sumpena, Huiyun Liu, Sarah M Duquette and 11 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Ye ZhangKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0003-3057-6759
Lydie DebaizeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-3718-3210
Adam LangenbucherComputational and Systems Biology Program, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-6291-580X
Jenalyn WeekesDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0007-6380-4259
Ioulia VogiatziDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-3518-8042
Teemu P MiettinenKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0002-5975-200X
Mingzeng ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-6875-8940
Emily SumpenaDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0009-0003-7701-0821
Huiyun LiuDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sarah M DuquetteKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0009-0004-9178-5604
Liam HackettDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Jeremy ZhangDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Sona BaghiyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Robert A ReddDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.
Martin AryeeDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA.ORCID 0000-0002-6848-1344
Matthew S DavidsDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Austin I KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0003-1039-0658
Christine E RyanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
David M WeinstockDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Scott R ManalisKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA, USA.ORCID 0000-0001-5223-9433
Mark A MurakamiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID 0000-0001-9520-2876

Funding

VIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9M
Graduate Training in Computational and Systems BiologyT32GM087237 · NIGMS · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BURGE, CHRISTOPHER B · 2009 to 2023
$4.6M
Targeting High-Risk Lymphoid NeoplasmsR35CA231958 · NCI · DANA-FARBER CANCER INST · PI WEINSTOCK, DAVID MARC · 2019 to 2021
$2.9M
NCI NIH HHS P30 CA014051NCI NIH HHS R35 CA231958NIGMS NIH HHS T32 GM087237
6 · The paper itself

Abstract

Intra-tumor heterogeneity impacts disease progression and therapeutic resistance but remains poorly characterized by conventional histologic, immunophenotypic, and molecular approaches. Single-cell biophysical properties distinguish functional phenotypes complementary to these approaches, providing additional insight into cellular diversity. Here we link both buoyant mass and stiffness to gene expression to identify clinically relevant phenotypes within primary mantle cell lymphoma (MCL) cells, employing MCL as a model of biological and clinical diversity in human cancer. Linked measurements reveal that buoyant mass and stiffness characterize B-cell development states from naïve to plasma cell and correlate with expression of oncogenic B-cell receptor signaling genes such as

Identifiers

PMID40475412
PMCPMC12139831

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.